G&S Research promotes Mike Bandick to SVP

Healthcare marketing research firm G&S Research promoted Mike Bandick to SVP. The move follows a company restructuring that put Bandick at the head of R&S Research's client solutions group.

George Grubb, principal of G&S Research, said in a statement that Bandick's leadership has been “instrumental in navigating the complex opportunities and recent economic contraction of the biopharmaceutical market space that we serve.”

Bandick joined R&S Research in 2006 as VP and business unit leader, and will remain a member of the company's executive committee. Prior to joining R&S Research, Bandick was senior director of marketing for Suros Surgical Systems, which was acquired by Hologic. Before that, Bandick worked in several capacities with Eli Lilly, and was most recently a global marketing director on Cymbalta, Lilly's antidepressant and pain treatment. He also worked on Zyprexa, Lilly's schizophrenia and bipolar drug. 
You must be a registered member of MMM to post a comment.

Email Newsletters

Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.